U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C11H10N2O2
Molecular Weight 202.2093
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VASICINONE

SMILES

O[C@H]1CCN2C1=NC3=C(C=CC=C3)C2=O

InChI

InChIKey=SDIVYZXRQHWCKF-VIFPVBQESA-N
InChI=1S/C11H10N2O2/c14-9-5-6-13-10(9)12-8-4-2-1-3-7(8)11(13)15/h1-4,9,14H,5-6H2/t9-/m0/s1

HIDE SMILES / InChI

Description

Vasicinone is a quinazoline alkaloid. Hepatoprotective activity of vasicinone has being shown in mice. Pre-treatment with vasicinone and silymarin (25 mg/kg/day for 7 days) significantly decreased CCl4-induced increase in SGOT, SGPT, ALP levels. Vasicinone has shown cytotoxic and antiproliferative activity in several tumor cell lines. Vasicinone, an oxidation product of vascinine is a potent bronchodialator. Vasicinone could be utilised in alternate anti asthmatic therapy, since it plays a vital role in scavenging Nitric oxide which could prevent the bronchial inflammation in asthmatic patients.

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
Rats experimental arthritis model: maximum inhibition rate was observed of vasicinone (63.94%) atter dose of 10.0 mg/kg p.o at 4 days after CFA injection.
Route of Administration: Oral
In Vitro Use Guide
The concentration of vasicinone needed to inhibit the incorporation of {(3)H-TDR} in the DNA cells of Jurkat, E6-1 clone by 50% (IC50) were 8.60 ± 0.023 ug/mL